GSK Partners with Imperial and Oxford to Launch £11M Digital Organ Twins Center for Drug Discovery
核心洞察
GSK, Imperial College London, and the University of Oxford have established the Modelling-Informed Medicine Centre (搜索) (MiMeC (搜索)) with £11 million funding to create digital twins of organs for accelerated drug discovery.
The center will build computer models of lungs (搜索), liver (搜索), and kidneys (搜索) to better understand disease progression and enable virtual experiments at a fraction of traditional costs.
GSK plans to integrate organ models into its drug development pipeline within five years, with researchers able to simulate treatment responses and optimize dosing strategies.
GSK has partnered with Imperial College London and the University of Oxford to establish the Modelling-Informed Medicine Centre (搜索) (MiMeC (搜索)), a £11 million initiative that will create digital twins of human organs to accelerate drug discovery and development. The center represents a new UK hub for research in the emerging field of modelling-informed medicine, focusing on organs including the lungs (搜索), liver (搜索), and kidneys (搜索).
Revolutionary Approach to Drug Development
Digital twins are virtual versions of organs that enable researchers to conduct simulated experiments on computers rather than relying solely on laboratory testing. Professor Steven Niederer from Imperial's National Heart and Lung Institute explained the transformative potential: "We have seen maths used for modelling aeroplanes and cars, and increasingly there is a realisation that this has benefits in biology, where you can perform virtual experiments in models of humans at great speed and a fraction of the usual cost."
The center's approach differs significantly from computational methods that merely identify statistical patterns in biological data. Instead, these mechanistic models represent cause-and-effect relationships, potentially making them more explainable and robust for drug development applications.
Technical Implementation and Capabilities
At Imperial College London, Professor Niederer's team will construct patient-specific organ models using artificial intelligence and biological datasets. They will mathematically represent millions of cells in organs such as the lungs (搜索), modeling the mechanistic relationships between cells by representing a proportion of cells found in the actual organ.
Using these models, researchers could perform a simple laboratory experiment on the effect of a drug on a single lung cell and then simulate how this would translate into larger effects, such as changes in airway behavior. This capability could eventually allow clinicians to use digital twins of specific patients to tailor treatments in real time, an approach that Professor Niederer's group is already testing with cardiac patients.
The University of Oxford will contribute by developing and applying mechanistic models grounded in physics, physiology, and pharmacology to advance understanding of disease processes and inform the design of more effective treatments. These will include multi-scale models that integrate molecular, cellular, and organ-level processes with whole-body physiology.
Strategic Implementation Timeline
GSK plans to incorporate organ models into its drug development pipeline within five years, supported by industrial placements provided to researchers from the center. Dr Anna Sher, MiMeC (搜索) Co-Director and Quantitative Systems Pharmacology lead in GSK's Respiratory, Immunology and Inflammation Research Unit, outlined the strategic approach: "By cycling between computer modelling, learning from the results, making predictions and then testing them, we can make faster, better decisions in developing new medicines."
The tools and models developed through MiMeC (搜索) will strengthen GSK's ability to generate virtual patients and digital twins to run computer-based clinical trials, analyze different data types, and test scientific ideas more efficiently.
Collaborative Framework and Open Science
The center aims to address fragmentation in the field by bringing together research efforts and training a new generation of research and development specialists. The initiative will share its models on an open-source basis and build collaborations with additional partners, contributing open-source tools, standards for reproducibility, and case studies that demonstrate the impact of model-informed drug development.
Professor Jon Chapman, head of the Mathematical Institute at the University of Oxford, emphasized the significance of the partnership: "This exciting new partnership recognises the pioneering role that the Wolfson Centre for Mathematical Biology has played, and continues to play, in applying mathematics to understand diseases and their response to treatment."
The program is led by Professor Steven Niederer at Imperial College London, Professors Helen Byrne and Philip Maini at the University of Oxford, and Dr Anna Sher at GSK. MiMeC (搜索) will focus on adopting a mathematical modelling-first mindset in the development of new therapies, with the potential to help accelerate the UK life science industry through mechanistic modelling approaches in quantitative medicine.